October 20, 2026
AI agents move into drug development management: OpenAI buys Orchestra Bio

OpenAI announced on Oct 20 that it is buying Orchestra Bio; financial terms were not disclosed. Orchestra builds an R&D management platform for life sciences: it plans and tracks drug development programs, while AI agents monitor progress, risks and results against the scientific and financial plan.
Source